Glutamatergicheskaya terapiya bolezni Al'tsgeymera
- Authors: Kolykhalov I.V1
-
Affiliations:
- Issue: No 3S (2015)
- Pages: 44-49
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/288514
- ID: 288514
Cite item
Open Access
Access granted
Abstract
For effective pharmacological correction of the various stages of Alzheimer’s disease (AD) should be used already developed the therapy algorithms. Cholinesterase inhibitors (CEI) approved as a standard first-line therapy in patients with mild to moderate AD. Memantine may be used as monotherapy or in combination with a CEI for patients with moderate AD, and as monotherapy for patients with severe AD.The results of generalised analysis show that memantine potentially effective and well tolerated in patients with moderate to severe AD. Memantine has a positive effect on cognitive function and also benefits for language function. It has a positive effect on the behavioral and psychotic symptoms, including irritability and aggression, which are known to be associated with rapid disease progression and increased caregiver burden. Since the mechanism of action of memantine different for CEI, we can suppose that memantine can be effective in patients with resistance or poor quality of response CEI. Furthermore, memantine can be administered in the early stage of AD, in patients with language disorders.
Keywords
Full Text
References
- Greenamyre J.T., Penney J.B., D'Amato C.J., Young A.B. Dementia of the Alzheimer's type: changes in hippocampal L-[3H] glutamate binding. J. Neurochem. 1987; 48(2): 543-51.
- Ditzler K. Efficacy and tolerability of memantine in patients with dementia syndrome. Drug Res. 1991; 41: 73-8.
- Гаврилова С.И., Калын Я.Б., Колыхалов И.В., Михайлова Н.М., Рощина И.Ф., Селезнева Н.Д., Жариков Г.А., Радзивилл Г.Г. Акатинол мемантин - модулятор глутаматергической системы в лечении деменций альцгеймеровского типа. Соц. и клин. псих. 1995; 2: 78-89.
- Gottfries C.G., Brane G., Gullberg B., Steen G. A new rating scale for dementia syndromes. Arch. Gerontol. Geriatr. 1982; 1(4): 311-30.
- Гаврилова С.И., Селезнева Н.Д., Колыхалов И.В., Калын Я.Б. Эффективность глутаматергической терапии при болезни Альцгеймера на стадии мягкой деменции. Соврем. тер. псих. расстр. 2007; 3: 43-9.
- McClendon M.J., Hernandez S., Smyth K.A., Lerner A.J. Memantine and acetylcholinesterase inhibitor treatment in cases of CDR 0.5 or questionable impairment. J. Alzheimers Dis. 2009; 16(3): 577-83.
- Schneider L.S., Sano M. Current Alzheimer's disease clinical trials: methods and placebo outcomes. Alzheimers Dement. 2009; 5(5): 388-97.
- Roberts J.S., Karlawish J.H., Uhlmann W.R., Petersen R.C., Green R.C. Mild cognitive impairment in clinical care: a survey of American Academy of Neurology members. Neurology. 2010; 75(5): 425-31.
- Peskind E.R., Potkin S.G., Pomara N., Ott B.R., Graham S.M., Olin J.T., McDonald S. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am. J. Geriatr. Psychiatr. 2006; 14(8): 704-15.
- Porsteinsson A.P., Grossberg G.T., Mintzer J., Olin J.T., Memantine MEM-MD-12 Study Group. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr. Alzheimer Res. 2008; 5(1): 83-9.
- Schneider L.S., Dagerman K.S., Higgins J.P., McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch. Neurol. 2011; 68(8): 991-98.
- Matsunaga S., Kishi T., Iwata N. Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis. PLoS One. 2015; 10(4): e0123289.
- Zhang N., Wei C., Du H., Shi F.D., Cheng Y. The Effect of Memantine on Cognitive Function and Behavioral and Psychological Symptoms in Mild-to-Moderate Alzheimer's Disease Patients. Dement. Geriatr. Cogn. Disord. 2015; 40(1-2): 85-93.
- Farlow M.R., Cummings J.L. Effective pharmacologic management of Alzheimer's disease. Am. J. Med. 2007; 120(5): 388-97.
- Ruther E., Glaser A., Bleich S., Degner D., Wiltfang J. A prospective PMS study to validate the sensitivity for change of the D-scale in advanced stages of dementia using the NMDA-antagonist memantine. Pharmacopsychiatry. 2000; 33: 103-8.
- Reisberg B., Doody R., Stöffler A., Schmitt F., Ferris S., Möbius H.J. Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 2003; 348: 1333-41.
- Гаврилова С.И., Калын Я.Б., Селезнева Н.Д. Колыхалов И.В., Жариков Г.А., Котова В.С. Глутаматергическая терапия болезни Альцгеймера на стадии умеренно-тяжелой и тяжелой деменции: результаты 26 недельного исследования эффективности и безопасности препарата акатинол мемантин. Журнал невропат. и психиатр. им. С.С. Корсакова. 2005; 2: 72-6.
- Колыхалов И.В., Гаврилова С.И., Калын Я.Б., Селезнева Н.Д., Федорова Я.Б. Сравнительное клиническое исследование безопасности и переносимости одноразового приема препарата акатинол мемантин в сравнении с двухразовым приемом у пациентов с умеренно выраженной и умеренно-тяжелой деменцией при болезни Альцгеймера. Журнал невропат. и психиатр.
- Ferris S., Ihl R., Robert P., Winblad B., Gatz G., Tennigkeit F., Gauthier S. Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients. Alzheimers Dement. 2009; 5(5): 369-74.
- Francis P.T. Altered Glutamate Neurotransmission and Behaviour in Dementia: Evidence from Studies of Memantine. Curr. Mol. Pharmacol. 2009; 2: 77-82.
- Senanarong V., Cummings J.L., Fairbanks L., Mega M., Masterman D.M., O'Connor S.M., Strickland T.L. Agitation in Alzheimer's disease is a manifestation of frontal lobe dysfunction. Dement. Geriatr. Cogn. Disord. 2004; 17: 14-20.
- van Dyck C.H., Tariot P.N., Meyers B., Malca Resnick E. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2007; 21: 136-43.
- Donaldson C., Tarrier N., Burns A. Determinants of carer stress in Alzheimer's disease. Int. J. Geriatr. Psychiatry. 1998; 13: 248-56.
- Gauthier S., Loft H., Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Int. J. Geriatr. Psychiatry. 2008; 23: 537-45.
- Jones R.W., Bayer A., Inglis F., Barker A., Phul R. Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease. Int. J. Geriatr. Psychiatry. 2007; 22(3): 258-62.
- Schulz J.B., Rainer M., Klünemann H.H., Kurz A., Wolf S., Sternberg K., Tennigkeit F. Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial. J. Alzheimers Dis. 2011; 25(3): 463-75.
Supplementary files
